An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Type2 Diabetes Clinical Trial

— ORION-3  

Official title:

An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03060577
• Other study ID #: MDCO-PCS-16-01
• Secondary ID: 2016-003815-37
• Status: Completed
• Phase: Phase 2
• Start date: April 27, 2017
• Est. completion date: December 17, 2021

Study information

• Verified date: February 2023
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical study was designed to assess the efficacy, safety, and tolerability of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in participants with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).

Description:

MDCO-PCS-16-01 (ORION-3) was a Phase II, open-label, multicenter, non-randomized, active comparator long term extension study. Total study duration was 4 years from first participant enrolled to the last subject completed. The study consisted of three study periods: Screening Period: Participants completing study MDCO-PCS-15-01 (ORION-1) were screened for all inclusion and exclusion criteria of study ORION-3. Treatment Period: Participants fulfilling all eligibility criteria of ORION-3 were enrolled. Participants who received inclisiran in ORION-1 received inclisiran sodium throughout this study up to 4 years (Group 1; Inclisiran-only arm), and participants who received placebo in ORION-1 received evolocumab as open-label comparator up to Day 336, and then transitioned to inclisiran on Day 360 and every 180 days thereafter for up to 4 years (Group 2; Switching arm). Safety follow up: Participants were followed up for safety during 4 weeks after the last dose of study treatment. Including the Screening Period, the total study duration for a participant was up to 4 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 382
• Est. completion date: December 17, 2021
• Est. primary completion date: December 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Completion of Study MDCO-PCS-15-01 and no contraindication to receiving inclisiran or evolocumab.

2. Willing and able to give written and informed consent before initiation of any study related procedures and willing to comply with all required study procedures.

3. Willing to self-inject.

Exclusion Criteria:

1. Any uncontrolled or serious disease, or any medical or surgical condition that may either interfere with participation in the clinical study and/or put the participant at significant risk (according to investigator's [or delegate's] judgment).

2. An underlying known disease or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate), might interfere with interpretation of the clinical study results.

3. Serious comorbid disease in which the life expectancy of the participant is shorter than the duration of the trial (for example, acute systemic infection, cancer, or other serious illnesses).

4. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver; unexplained alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation greater than 2 times upper limit of normal (ULN); or total bilirubin elevation greater than 1.5 times ULN at study entry visit.

5. Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least two methods of contraception (for example, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion are

• Women >2 years postmenopausal (defined as 1 year or longer since their last menstrual period) AND more than 55 years of age
• Postmenopausal women (as defined above) and less than 55 years old with a negative pregnancy test within 24 hours of enrollment
• Women who are surgically sterilized at least 3 months prior to enrollment

6. Males who are unwilling to use an acceptable method of birth control during the entire study period (that is, condom with spermicide).

7. Treatment with investigational medicinal products other than inclisiran or devices within 30 days or five half?lives, whichever is longer.

8. Planned use of investigational medicinal products other than inclisiran or devices during the course of the study.

9. Participants with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients

10. Previous or current treatment (within 90 days of study entry) with monoclonal antibodies directed towards PCSK9.

11. Any condition that according to the investigator could interfere with the conduct of

the study, such as but not limited to:

• Inappropriate for this study, including participants who are unable to communicate or to cooperate with the investigator.
• Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency).
• Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (for example, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study).
• Involved with, or a relative of, someone directly involved in the conduct of the study.
• Any known cognitive impairment (for example, Alzheimer's Disease).

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerotic Cardiovascular Disease
• Cardiovascular Diseases
• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II
• Symptomatic Atherosclerosis
• Type2 Diabetes

Intervention

Drug:
• Inclisiran
Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
• Evolocumab
Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.

Locations

Country	Name	City	State
Canada	Novartis Investigative Site	Brampton	Ontario
Canada	Novartis Investigative Site	Chicoutimi	Quebec
Canada	Novartis Investigative Site	London	Ontario
Canada	Novartis Investigative Site	Montreal	Quebec
Canada	Novartis Investigative Site	Quebec
Canada	Novartis Investigative Site	Quebec
Canada	Novartis Investigative Site	Sherbrooke	Quebec
Canada	Novartis Investigative Site	St Johns
Canada	Novartis Investigative Site	Toronto	Ontario
Canada	Novartis Investigative Site	Vancouver	British Columbia
Canada	Novartis Investigative Site	Winnipeg	Manitoba
Germany	Novartis Investigative Site	Berlin
Germany	Novartis Investigative Site	Essen
Germany	Novartis Investigative Site	Frankfurt
Germany	Novartis Investigative Site	Heidelberg
Germany	Novartis Investigative Site	Munich
Netherlands	Novartis Investigative Site	Amsterdam
Netherlands	Novartis Investigative Site	Den Haag
Netherlands	Novartis Investigative Site	Deventer
Netherlands	Novartis Investigative Site	Eindhoven
Netherlands	Novartis Investigative Site	Goes
Netherlands	Novartis Investigative Site	Hoogeveen
Netherlands	Novartis Investigative Site	Hoogezand
Netherlands	Novartis Investigative Site	Hoorn
Netherlands	Novartis Investigative Site	Leiden	Zuid-Holland
Netherlands	Novartis Investigative Site	Rotterdam	The Netherlands
Netherlands	Novartis Investigative Site	Utrecht
Netherlands	Novartis Investigative Site	Utrecht
Netherlands	Novartis Investigative Site	Venlo
Netherlands	Novartis Investigative Site	Zwijndrecht
United Kingdom	Novartis Investigative Site	Birmingham
United Kingdom	Novartis Investigative Site	Edinburgh
United Kingdom	Novartis Investigative Site	Exeter
United Kingdom	Novartis Investigative Site	Fowey	Cornwall
United Kingdom	Novartis Investigative Site	High Wycombe
United Kingdom	Novartis Investigative Site	Liskeard	Cornwall
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Manchester
United Kingdom	Novartis Investigative Site	Newcastle Upon Tyme
United Kingdom	Novartis Investigative Site	Penzance	Cornwall
United Kingdom	Novartis Investigative Site	Plymouth
United Kingdom	Novartis Investigative Site	St Austell	Cornwall
United Kingdom	Novartis Investigative Site	Torpoint	Cornwall
United Kingdom	Novartis Investigative Site	Worcester
United States	Novartis Investigative Site	Amarillo	Texas
United States	Novartis Investigative Site	Cincinnati	Ohio
United States	Novartis Investigative Site	Cincinnati	Ohio
United States	Novartis Investigative Site	Greenville	Tennessee
United States	Novartis Investigative Site	Indianapolis	Indiana
United States	Novartis Investigative Site	Jacksonville	Florida
United States	Novartis Investigative Site	New York	New York
United States	Novartis Investigative Site	Richmond	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm)	Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score represents a reduction in LDL-C. Change is relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total)
Secondary	Percentage Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)	Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Secondary	Absolute Change in LDL-C From Baseline of the ORION-1 Study (Inclisiran Arm)	Absolute Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in LDL-C. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 360, 720, 1080 and 1440 (ORION-3) (up to 390, 720, 1080, 1440 and 1800 days total, respectively)
Secondary	Percentage Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)	Percent Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Secondary	Absolute Change in PCSK9 Levels From Baseline of the ORION-1 Study (Inclisiran Arm)	Absolute Change in PCSK9 from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in PCSK9. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Secondary	Percentage Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)	Percent Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Absolute Change in Triglycerides From Baseline of the ORION-1 Study (Inclisiran Arm)	Absolute Change in Triglycerides from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Triglycerides. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Percentage Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)	Percent Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Absolute Change in Apolipoprotein B From Baseline of the ORION-1 Study (Inclisiran Arm)	Absolute Change in Apolipoprotein B from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Apolipoprotein B. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Percentage Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)	Percent Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative percentage score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Absolute Change in Lipoprotein-a From Baseline of the ORION-1 Study (Inclisiran Arm)	Absolute Change in Lipoprotein-a from baseline of the ORION-1 Study overtime in ORION-3. A negative score represents a reduction in Lipoprotein-a. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 210 and 1440 (ORION-3) (up to 390, 570 and 1800 days total, respectively)
Secondary	Number of Participants With =50% LDL-C Reduction From Baseline of the ORION-1 Study (Inclisiran Arm)	Number of Participants with =50% LDL-C (beta-quantification) Reduction from baseline of the ORION-1 Study overtime in ORION-3. Changes are relative to ORION-1 Baseline, which is defined as the last available record prior to first study drug administration in ORION-1.	Baseline (ORION-1) and Days 30, 360, 720 and 1440 (ORION-3) (up to 390, 720, 1080 and 1800 days total, respectively)
Secondary	Number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL (Inclisiran Arm)	Individual responsiveness to inclisiran is defined as the number of Participants Reaching on Treatment LDL-C Levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL at any time point.	From the start of treatment in ORION-3 to 90 days after end of treatment, assessed up to maximum duration of 4 years